These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 22280526)

  • 1. Evaluation of prognostic factors and the role of chemotherapy in unfavorable carcinoma of unknown primary site: a 10-year cohort study.
    Chen KW; Liu CJ; Lu HJ; Tzeng CH; Liu JH; Chiou TJ; Yen CC; Wang WS; Chao TC; Teng HW; Chen MH; Liu CY; Chang PM; Yang MH
    BMC Res Notes; 2012 Jan; 5():70. PubMed ID: 22280526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy.
    Kodaira M; Takahashi S; Yamada S; Ueda K; Mishima Y; Takeuchi K; Yamamoto N; Ishikawa Y; Yokoyama M; Saotome T; Terui Y; Hatake K
    Ann Oncol; 2010 Jun; 21(6):1163-1167. PubMed ID: 20019088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of prognostic factors in 68 patients with cancer of unknown primary site].
    Kou XG; Liang DL; Zhang QQ; Li XR; Zhao YZ; Gu JF; Lu P
    Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):783-6. PubMed ID: 22335913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of prognosis for carcinoma of unknown origin in elderly patients.
    Lu HJ; Chen KW; Tzeng CH; Liu JH; Chiou TJ; Yen CC; Chao TC; Teng HW; Chen MH; Liu CY; Wang WS; Chang PM; Yang MH
    Oncology; 2012; 83(1):24-30. PubMed ID: 22722484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site.
    Seve P; Ray-Coquard I; Trillet-Lenoir V; Sawyer M; Hanson J; Broussolle C; Negrier S; Dumontet C; Mackey JR
    Cancer; 2006 Dec; 107(11):2698-705. PubMed ID: 17063500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.
    Pentheroudakis G; Briasoulis E; Kalofonos HP; Fountzilas G; Economopoulos T; Samelis G; Koutras A; Karina M; Xiros N; Samantas E; Bamias A; Pavlidis N;
    Acta Oncol; 2008; 47(6):1148-55. PubMed ID: 18607872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.
    van der Gaast A; Verweij J; Planting AS; Hop WC; Stoter G
    J Clin Oncol; 1995 Jul; 13(7):1720-5. PubMed ID: 7541451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study.
    Bourgeois H; Grudé F; Solal-Céligny P; Dupuis O; Voog E; Ganem G; Denis F; Zinger M; Juhel-Voog L; Lafond C; Maillart P; Capitain O; Delva R; Soulié P; Abadie-Lacourtoisie S; Guérin-Meyer V; Morin-Meschin ME; Commer JM; Gangler A; d'Aillières B; Zannetti A; Bourbouloux E; Berton-Rigault D; Lebouvier-Sadot S; Kaassis M; Baudon J; Lam YH; Bizieux A; Marcq M; Edeline J; Le Du F; Lefeuvre C; Deguiral P; Delecroix V; Blot E; Egreteau J; Goudier MJ; Lamy R; Ferec M; Artignan X; Corbinais S; Morel H; Hardy-Bessard AC; Alleaume C; Naudeix E; Cojocarasu O; Metges JP; Riché C; Gamelin E; Déniel-Lagadec D; Marhuenda F; Ingrand P; Douillard JY
    Ann Oncol; 2017 Jul; 28(7):1612-1617. PubMed ID: 28472235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carcinoma of unknown primary site: development in a single institution of a prognostic model based on clinical and serum variables.
    Ponce Lorenzo J; Segura Huerta A; Díaz Beveridge R; Giménez Ortiz A; Aparisi Aparisi F; Fleitas Kanonnikoff T; Richart Aznar P; de la Cueva Sapiña H; Montalar Salcedo J
    Clin Transl Oncol; 2007 Jul; 9(7):452-8. PubMed ID: 17652059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum lactic dehydrogenase strongly predicts survival in metastatic nasopharyngeal carcinoma treated with palliative chemotherapy.
    Jin Y; Ye X; Shao L; Lin BC; He CX; Zhang BB; Zhang YP
    Eur J Cancer; 2013 May; 49(7):1619-26. PubMed ID: 23266049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
    Koch A; Fohlin H; Sörenson S
    J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy.
    Yonemori K; Ando M; Shibata T; Katsumata N; Matsumoto K; Yamanaka Y; Kouno T; Shimizu C; Fujiwara Y
    J Cancer Res Clin Oncol; 2006 Oct; 132(10):635-42. PubMed ID: 16791594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of "unfavourable" carcinoma of unknown primary site: synthesis of recent literature.
    Amela EY; Lauridant-Philippin G; Cousin S; Ryckewaert T; Adenis A; Penel N
    Crit Rev Oncol Hematol; 2012 Nov; 84(2):213-23. PubMed ID: 22503530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile.
    Hainsworth JD; Schnabel CA; Erlander MG; Haines DW; Greco FA
    Clin Colorectal Cancer; 2012 Jun; 11(2):112-8. PubMed ID: 22000811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New prognostic index to predict survival in patients with cancer of unknown primary site with unfavourable prognosis.
    Trivanović D; Petkovic M; Stimac D
    Clin Oncol (R Coll Radiol); 2009 Feb; 21(1):43-8. PubMed ID: 18976894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment serum lactate dehydrogenase is an independent prognostic factor for patients receiving neoadjuvant chemotherapy for locally advanced cervical cancer.
    Li J; Wu MF; Lu HW; Chen Q; Lin ZQ; Wang LJ
    Cancer Med; 2016 Aug; 5(8):1863-72. PubMed ID: 27350066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Second-line chemotherapy in patients with primary unknown cancer.
    Ono M; Ando M; Yonemori K; Yamamoto H; Hirata T; Shimizu C; Tamura K; Katsumata N; Fujiwara Y
    J Cancer Res Clin Oncol; 2011 Aug; 137(8):1185-91. PubMed ID: 21559815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarcomatoid carcinoma presenting as cancers of unknown primary: a clinicopathological portrait.
    Huey RW; Makawita S; Xiao L; Matamoros A; Estrella JS; Overman MJ; Varadhachary GR; Raghav K
    BMC Cancer; 2019 Oct; 19(1):965. PubMed ID: 31623602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
    Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
    Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.
    Kodaira M; Yonemori K; Shimoi T; Yoshida A; Yoshida M; Kitano A; Shimomura A; Yunokawa M; Shimizu C; Takiguchi Y; Fujiwara Y; Tamura K
    BMC Cancer; 2018 Feb; 18(1):176. PubMed ID: 29433539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.